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Alpha synuclein (αsyn) aggregates are associated with the pathogenesis of Parkinson’s
disease and others related disorders. Although modulation of αsyn aggregation is
an attractive therapeutic target, new powerful methodologies are desperately needed
to facilitate in vivo screening of novel therapeutics. Here, we describe an in vivo
rodent model with the unique ability to rapidly track αsyn-αsyn interactions and thus
oligomerization using a bioluminescent protein complementation strategy that monitors
spatial and temporal αsyn oligomerization ex vivo. We find that αsyn forms oligomers
in vivo as early as 1 week after stereotactic AAV injection into rat substantia nigra.
Strikingly, although abundant αsyn expression is also detected in striatum at 1 week,
no αsyn oligomers are detected at this time point. By 4 weeks, oligomerization of
αsyn is detected in both striatum and substantia nigra homogenates. Moreover, in a
proof-of-principle experiment, the effect of a previously described Hsp90 inhibitor known
to prevent αsyn oligomer formation, demonstrates the utility of this rapid and sensitive
animal model to monitor αsyn oligomerization status in the rat brain.
Keywords: alpha-synuclein, oligomers, protein-fragment complementation, bioluminescence, viral vector model
INTRODUCTION
Under pathological conditions alpha-synuclein (αsyn) can misfold and aggregate into insoluble
deposits that accumulate in cells to toxic levels. The conversion of αsyn from its functional
conformation into a misfolded and toxic conformation constitutes the basis of a group of diseases
known as synucleinopathies which include Parkinson’s disease (PD), multiple system atrophy,
and dementia with Lewy bodies (Goedert and Spillantini, 1998; Kim et al., 2014). Several lines
of evidence demonstrate a strong association between αsyn aggregation and neurodegeneration
(Irizarry et al., 1998; Chartier-Harlin et al., 2004; Winner et al., 2011). Fibrillar forms of αsyn are
themajor component of glial cytoplasmic inclusions, Lewy bodies (LBs), and Lewy neurites, defined
as intracytoplasmatic inclusions and considered the pathological hallmarks of synucleopathies
(Forno, 1996; Spillantini et al., 1997; Halliday et al., 2011). Normally, αsyn is a soluble, presynaptic
protein that may exist as a natively unfolded monomer or a functional tetramer (Bartels et al.,
2011; Wang et al., 2011; Fauvet et al., 2012; Burré et al., 2013; Gurry et al., 2013; Selkoe et al., 2014;
Dettmer et al., 2015a,b). The processes that lead to pathological aggregate formation occur through
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the formation of several soluble oligomeric intermediates that
mature into the insoluble amyloid fibrils found in LBs. It has
been proposed that prefibrillar forms of αsyn are the disease-
causative toxic species, while the insoluble fibrils might represent
a protective pathway for surviving cells (Ross and Poirier, 2004;
Paleologou et al., 2009; Winner et al., 2011; Kalia et al., 2013).
Although the mechanisms of αsyn-induced toxicity remain
unclear, inhibition of oligomerization represents an attractive
therapeutic approach. Such a strategy requires the availability
of powerful cellular and rodent models. Current methods for
detection of αsyn oligomers are challenging due to their dynamic
nature and sensitivity to external conditions (Uversky, 2003;
Drescher et al., 2012; Gurry et al., 2013) Thus, far, oligomer
studies have used indirect methods and biochemical techniques
that prohibit the study of αsyn oligomerization in a live cellular
environment or in intact brain. More recently, protein fragment
complementation assay (PCA) strategies that allow the detection
of αsyn-αsyn interactions using fluorescence or bioluminescent
reporters, have been widely developed and have been successfully
applied to monitor αsyn oligomers not only in living cells
(Outeiro et al., 2008; Putcha et al., 2010; Danzer et al., 2012) but
also in rodent brain (Dimant et al., 2013, 2014; Aelvoet et al.,
2014; McFarland et al., 2014).
Here, we generated and characterized a viral vector rodent
model where humanized Gaussia princeps luciferase (hGluc) is
used as a surrogate reporter of αsyn oligomerization in vivo in a
fast, sensitive, and semi quantitative assay. We demonstrate that
this rodent model can be utilized to track αsyn oligomerization
in vivo and validate the potential use of the model by testing
a novel Hsp90 inhibitor compound, known to reduce αsyn
oligomerization in vitro, on our in vivo bioluminescence read out.
MATERIALS AND METHODS
Viral Vector Production
The viral vectors pAAV-CBA-synuclein-LUC1-WPRE (SL1) and
pAAV-CBA-SYNUCLEIN-luc2-WPRE (SL2) were constructed
by inserting the human SNCA cDNA (h αsyn) fused to either
the N-terminus half of humanized G. princeps luciferase (hGluc)
(Tannous et al., 2005) or the C-terminus half of hGluc, into
the EcoRV and NheI sites of the pAAV-CBA-WPRE. Viral
vector pAAV-CBA-G. princeps luciferase was constructed by
inserting the full length of hGluc gene into the XhoI and
NheI sites of pAAV-CBA-WPRE vector. Adeno-associated virus
(AAV) serotype 2/8 was produced by plasmid transfection with
helper plasmids in HEK293T cells. Forty-eight hours later, the
cells were harvested and lysed in the presence of 0.5% sodium
deoxycholate and 50µ/ml Benzonase (Sigma-Aldrich, St. Louis,
MO) by freeze-thawing, and the virus was isolated using a
discontinuous iodixanol gradient. The genomic titer of each virus
was determined by quantitative PCR.
Surgical Procedure
Adult Female Sprague Dawley rats (225–250 g, Harlan, USA)
were housed and treated in accordance with the NIH Guide
for Care and Use of Laboratory animals. All procedures were
approved and conducted in accordance with the Mayo Clinic
Institutional Animal Care and Use committee. Rats were housed
3 per cage with ad-libitum access to food and water during a
12 h light/dark cycle. Surgery was conducted under 2% isoflurane
anesthesia mixed with O2 and N2 using a stereotaxic frame
and a 10µl Hamilton syringe fitted with a 30 gauge needle.
The scalp was exposed and a unilateral injection targeting the
substantia nigra (SN) was performed at coordinates 5.2mm
posterior and 2mm lateral to bregma, and 7.2mm ventral relative
to dura. AAV8 vectors were normalized by titer and volume,
resulting in injection of an equal amount of genomes per copy
per vector. Twomicroliter of a mixture of two viruses (SL1 8.1012
g/ml + SL2 8.1012 g/ml) were injected at a rate of 0.4µl/min using
a microinjection pump (Stoelting Co, Wood Dale, IL). Control
animals were injected with one virus only (2µl of AAV8-SL2
at 16.1012 genome/ml), or received one injection of 1µl of SL1
(8.1012 g/ml) in the SN of the left hemisphere (ML: −2mm)
and one injection of 1µl of SL2 (8.1012 g/ml) in the SN of
the other hemisphere (ML: 2mm). At the end of injection the
needle remained in place for 5min before being slowly retracted.
Animals were then sutured with metal clips and monitored until
fully recovered.
Tissue Processing
For histological analyses, animals were deeply anaesthetized
at 1 and 4 weeks post-injection with pentobarbital and
perfused transcardially with ice-cold 0.9% saline, followed by
4% paraformaldehyde (PFA). Brains were removed and post-
fixed for 4 h in the same solution and were then transferred
overnight to 25% sucrose solution for cryoprotection. The brains
were cross-sectioned using a freezing stage sliding microtome
(Leica SM2010R, Germany) at 40µm in the coronal plane. Brains
from a subset of animals from 1 to 4 weeks post injection were
harvested fresh without fixation. The two hemispheres were
separated and the striatum (STR) and midbrain from both sides
were quickly dissected on ice and used directly for biochemical
analysis.
Immunohistochemistry
Immunohistochemical analysis was performed on free-floating
sections (40µm) using primary antibodies against tyrosine
hydroxylase (TH) (1:3000, MAB318, Millipore), and hαsyn
(1:2000, 4B12, specific antibody to human form of αsyn,
Covance). Sections were washed with phosphate buffer saline
(PBS) before each incubation. After the initial wash, the sections
were quenched for 20min at RTwith PBS solution, supplemented
with 3% H2O2 (v/v) (Sigma-Aldrich), and 10% Methanol (v/v)
(Pharmaco-Aaper) and were then blocked with 5% goat serum
(Life technologies, Carlsbad, CA, USA) in T-PBS (0.25% Triton
dissolved in PBS). The sections were incubated overnight at
RT with one of the indicated antibodies, diluted in 2.5%
goat serum and T-PBS. After washing, the brain slices were
treated with 1:200 dilution of the appropriate biotinylated
secondary antibody (Vector Laboratories, Burlingame, CA, USA)
in 1% goat serum and T-PBS. Thereafter, the sections were
rinsed and incubated with avidin-biotin-peroxidase complex
(ABC peroxidase kit, Thermo Scientific). The staining was
visualized by 3,3-diaminobenzidine (DAB; Sigma-Aldrich) used
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as a chromagen and activated by 1% H2O2. The sections were
then mounted on gelatin-coated slides, dehydrated with alcohol,
cleared with xylene and coverslipped with DePex mounting
medium (Sigma-Aldrich).
Stereology
Nigrostriatal cell loss was assessed using an unbiased stereology
method using the optical fractionator principle as described
previously (West et al., 1991). Lower magnification was used to
trace the region of interest (SN in each hemisphere) at all levels
in the rostro-caudal axis in 9–10 sections per animals. TH+
cells in the ventral tegmental area (VTA) were excluded. The
counting was performed using the Stereo Investigator software
(MBF bioscience). In addition, the counting frame size was
adjusted so that ∼100–200 TH+ positive cells were counted in
each side of the SN. The estimation of total neuron numbers
was performed by using the optical fractionator formula and
coefficient of error <0.1 was accepted (West, 1999).
Densitometry
Images of forebrain were captured using the Aperio slide
scanner (Aperio, Vista, CA, USA). The optical density of striatal
TH+ fibers was measured using ImageJ software (Version
1.46, National Institutes of Health) at four coronal levels
according to the rat brain atlas of Paxinos and Watson (6th
edition, 2007): AP: +1.2,+ 0.8, 0.0 and −0.4mm relative
to bregma. The measured values were corrected for non-
specific background staining by subtracting values obtained from
adjacent cortical areas. The data are expressed as a percentage of
the corresponding area from the intact side.
Ex vivo Luciferase Complementation Assay
Fresh STR and SN were homogenized briefly in 200µl cold
PBS buffer using a Teflon pestle. One-hundred microliter of the
homogenate was transferred to a 96 well plate (Costar, Corning,
NY, USA) and the remainder was preserved for biochemical
analysis. Luciferase activity from αsyn-αsyn interaction was
measured in an automated plate reader (Victor 3 multilabel
counter, Perkin Elmer, Waltham, MA, USA) at 480 nm following
the injection of 100µl of the substrate coelenterazine (40µm,
NanoLight tech, AZ, USA) with a signal integration of 2 s.
Human αsyn Elisa
Quantitative analysis of hαsyn concentration in rat tissue was
performed using hαsyn specific ELISA (#KHBOO61, Life tech)
according to the manufacturer’s instructions. Absorbance at
450 nm is directly proportional to the concentration of hαsyn
present in the original specimen. αSyn concentrations were
normalized to the total amount of protein in the homogenate.
Protein content was measured using Bicinchoninic acid assay
(BCA) (Thermo Fisher Scientific, Waltham, MA, USA).
Western Blotting
Striatal and midbrain samples were suspended in RIPA
buffer (Millipore, 20-188) containing protease inhibitor (Roche
Diagnostics), homogenized on ice, and centrifuged at 13,000 × g
for 10min. Protein concentration of each lysate was determined
by BCA. Twenty microgram proteins was loaded on a denaturing
4–12% Bis- Tris gradient gel (Nupage, Novex Gel, Life tech) and
run according to the manufacturer’s instructions. Subsequently,
separated protein was transferred to polyvinylidene difluoride
(PVDF) membrane, blocked in 5% non-fat milk in TBS-T,
and immunoblotted for Hsp70 (1:5000, rabbit, ADI-SPA-812,
Enzo). Anti-actin (1:10000, rabbit polyclonal, A2668, Sigma-
Aldrich) was used as a loading control. All membranes were then
incubated with a secondary antibody conjugated to HRP for 1 h
at room temperature. Immunoreactivity was visualized using an
ECL chemiluminescent detection Kit (Thermo Fisher Sci) and
images were acquired with a CCD imaging system (LAS-4000,
Fujifilm, Japan).
SNX-9114 Treatment In vivo
SNX-9114 (Pfizer, PF-04944733) was described previously
(McFarland et al., 2014) and was dissolved in a 0.5%
methylcellulose solution before use. SNX-9114 was administered
at a dose of 2mg/kg by oral gavage twice for 1 week in a
volume of 1mL. As a control, the same volume of vehicle (0.5%
methylcellulose) was simultaneously administered in a separate
group of rats (vehicle group). SNX-9114 administration started 2
days after the stereotactic viral injection.
Cell Cultures
H4 neuroglioma cells (ATCC, HTB-148, Manassas, USA) were
maintained in Opti-MEM supplemented with 10% Fetal Bovine
Serum (FBS). H4 cells were transfected with full length hGluc
using Superfect transfection reagents (Qiagen, Chatsworth, CA,
USA) with an equimolar ratio of plasmids according to the
manufacturer’s instructions.
A tetracycline-driven stable H4 cell line co-expressing hαsyn
tagged with either the amino-terminal (SL1) or the carboxy-
terminal fragments (SL2) of hGluc luciferase was generated and
described previously (Moussaud et al., 2015). SL1SL2 cells were
cultured in Opti-MEM supplemented with 10% FBS, 200µg/ml
geneticin, 200µg/ml hygromycin B, and 1µg/ml tetracycline to
block the expression of the transgenes (SL1 and SL2). Cells were
maintained at 37◦C in a 95% air/5% CO2 humidified incubator
and all the cell cultures reagents were from Life technologies.
SL1SL2 stable cells were seeded into 6-well plates at the density
of 1 × 105 cells/well and in a 96-well plate at the density of 3 ×
104 cells/well in the absence of tetracycline. Twenty-four hours
later, media was replaced with FBS-free media supplemented
with SNX-9114 (25, 50, 100, or 200 nM) or with DMSO alone
as control. After 24 h treatment, cells in the six well plates were
lysed (150mM NaCl, 5mM Trisbase, 0.1% TritonX, cOmplete
Mini, pH 7.4) and analyzed by western blotting using antibodies
against: hαsyn (1:1000,mouse, 610787, Becton Dickinson, NJ,
USA), Hsp70 (1:5000, rabbit, ADI-SPA-812, Enzo life), and actin
(1:10000; rabbit polyclonal, A2668, Sigma-Aldrich), whereas cells
in 96 well plates were used for luciferase activity measurement as
described previously (Putcha et al., 2010).
Statistics
Data were analyzed using GraphPad Prism 6 (SanDiego, CA) and
are presented as mean ± standard error of the mean (S.E.M.).
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Statistical significance was determined using a Student’s t-test or
one-way analysis of variance with Tukey’s multiple comparison
post-hoc. P < 0.05 was considered significant.
RESULTS
Ex vivo Monitoring of αsyn Oligomers
using Bioluminescent PCA
The bioluminescent αsyn PCA strategy has been widely used
by our lab and others (Outeiro et al., 2008; Putcha et al.,
2010; Danzer et al., 2011; Moussaud et al., 2015) to investigate
αsyn oligomerization in living cells. Briefly, two hαsyn proteins
fused to N- or C-terminal halves of a reporter protein can
reconstitute the enzymatic activity of the reporter when αsyn-
αsyn interactions occur, thus providing a readout of αsyn-
αsyn interactions and oligomerization. In this study, two AAV8
vectors expressing hαsyn fused with either the N-terminus or
C-terminus of hGluc (referred hereafter as AAV-SL1 and AAV-
SL2) were stereotactically co-injected unilaterally into the SN
of adult rats to establish the in vivo bioluminescent PCA.
Previous studies from our lab have characterized the oligomeric
species formed in the bioluminescent complementation assay
as a heterogeneous population of soluble dimers and higher
order multimers (Danzer et al., 2011; Dimant et al., 2013). The
term oligomer is used henceforth to represent the heterogenous
population.
Delivery of AAV-SL1 and AAV-SL2 into the SN of the
rat produces widespread overexpression of hαsyn along the
nigrostriatal pathway as revealed by histological analysis
(Figures 1A,B). Immunostaining with an antibody specific for
hαsyn shows numerous cell bodies in the SN expressing the
transgenes at 1 week and at 4 weeks while the non-injected side
is devoid of hαsyn and is used as an internal control (Figure 1A).
Transport of virally transduced αsyn is indicated by the extensive
network of αsyn positive fibers at the striatal level (Figure 1B).
Hαsyn is observed along the axons from neurons of the SN,
terminating in the STR. Expression of hαsyn is detected from the
most anterior to the most posterior extent of the STR. This event
seems to happen rapidly after the viral injection since expression
of the transgenes in the terminals is observed after 1 week.
(Figure 1B, injected side). Moreover, these data demonstrate that
the luciferase reporter does not affect the ability of hαsyn protein
to be transported along the nigrostriatal pathway.
Because the substrate for hGluc, coelenterazine, does not
permeate the blood brain barrier, in vivo luciferase signal
was measured in homogenates ex vivo from the SN and STR
overexpressing tagged hαsyn at 1 week (n = 7) and at 4
weeks (n = 8) post injection. In each group, all brains were
processed at the same time and under the same conditions.
During homogenization no detergent, no intense shaking, and
no sonication are used. The tissue is briefly homogenized in
PBS with a tissue grinder pestle and vortexed for 1min. The
contralateral non-injected sides (STR and SN) were processed
in the same manner and served as internal controls for non-
specific background signal. Interestingly, luciferase activity could
be detected in the injected SN as early as 1 week post injection
(Figure 2A), increasing dramatically by 13-fold at 4 weeks
(Figure 2A). By contrast, in the STR, no luciferase activity is
detected at 1 week post injection (Figure 2B) whereas, abundant
luciferase activity is detected at 4 weeks (Figure 2B). The
luciferase signal in tissue homogenate from injected animals
indicates in vivo luciferase complementation, the surrogate
marker of αsyn-αsyn interactions. As expected, in animals
injected with only one half (AAV-SL2 only), no luciferase activity
was detected after 4 weeks (Supplementary Figures 1A,B)
demonstrating that fragmented luciferase does not give rise to
aberrant luminescence signal. A second control incorporated into
our experimental paradigm was a group of animals injected with
one half of the complementation pair (AAV-SL1) in the left SN
FIGURE 1 | AAV8 SL1SL2 transduction results in human αsyn over-expression along the nigrostriatal pathway. (A,B) Representative brightfield
photomicrographs of SN (A) and STR (B) at 1 and 4 weeks. Coronal sections immunostained with an antibody specific for hαsyn (clone 4B12) had expression of the
transgenes in the injected SN (A). The expression was also detected at the striatal level (B) with a more intense staining at 4 weeks, scale bar A, 1mm; B, 500µm.
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FIGURE 2 | Monitoring of αsyn oligomerization ex vivo using protein complementation assay. (A,B) αsyn oligomers were quantified via luciferase assay in
brain homogenates at 1 and 4 weeks after stereotaxic injection of SL1 and SL2. Signal detected in the non-injected side was used as a baseline. (A) In the SN, αsyn
oligomers were detected at 1 week, increasing significantly by 4 weeks [n = 6 per group, Student t-test, T(10) = 3.6; **p < 0.001]. (B) In the STR no luciferase activity
was detected at 1 week, but were observed by 4 weeks [n = 6 per group, Student’s T-test, T(10) = 2.4; *p < 0.05]. (C,D) represent the total expression of h-αsyn
assessed by ELISA in the homogenates of the SN (C) and STR (D) at 1 and 4 weeks. The data are expressed as the amount of h-αsyn normalized to the total amount
of proteins in the homogenates. Statistical analysis showed no significant differences across the time for each regions (p > 0.05, n = 6 per group). In (A,B) number
sign indicates significant differences between the injected side at 1 week and 4 week (#p < 0.05). n.s, not significant.
and the other half (AAV-SL2) in the right SN. After 4 weeks,
homogenates from left and right SN or STR were mixed together
and assayed for luciferase activity. As expected, no luciferase
activity was detected (Supplementary Figure 1C) demonstrating
that αsyn-αsyn interactions occur in vivo and not ex-vivo during
tissue processing.
Reconstitution of luciferase activity in vivo demonstrates the
successful complementation of luciferase halves via the formation
of αsyn oligomers. Importantly, our data show the presence of
αsyn oligomers in the SN as early as 1 week post-delivery of
AAV-SL1 and AAV-SL2 (Figure 2A). The total level of hαsyn
in the SN of the animals was quantified by ELISA at 1 and
4 weeks (Figure 2C). No significant difference was detected in
hαsyn levels 1 and 4 weeks (Figure 2C, 1 week = 0.90 ± 0.05
4 weeks = 0.88 ± 0.22, p > 0.05). Interestingly, although
equivalent levels of hαsyn was detected in SN at 1 and 4 weeks,
the oligomeric profile was very different (Figure 2A). No hαsyn
oligomers were detected in the STR at 1 week (Figure 2B)
despite abundant expression of αsyn by ELISA quantification
(Figure 2D). There are two ways these data can be interpreted;
αsyn oligomers form in the SN and are then transported to
the striatal terminals which takes longer than a week or that
oligomers form at the terminals over a longer period of time
(Figure 2B). Regardless, the data support the fact that sub-
cellular location affects αsyn oligomerization kinetics.
SL1 and SL2 Overexpression Induce
Progressive Nigral and Striatal
Dopaminergic Neurodegeneration
Previous viral vector rodent models of αsyn overexpression
have described a progressive nigral cell loss and striatal
terminal neurodegeneration (Kirik et al., 2002; Klein et al.,
2002). To confirm that our in vivo αsyn-αsyn bioluminescent
complementation model exhibits similar characteristics, we
immunostained coronal sections at the level of the SN and
STR with an antibody against tyrosine hydroxylase (TH),
and performed unbiased stereology and densitometry analysis.
At 1 week, TH immunostaining and stereology of the SN
indicated no loss of TH+ neurons in the injected side
overexpressing SL1 and SL2 when compared to the non-
injected side (Figure 3A). However, by 4 weeks a general
reduction in the dendritic arborization in the SN of the animals
was observed (Figure 3A) with stereological quantification
confirming a 38.5 ± 7.5% dopaminergic cell loss in animals
expressing SL1 and SL2 (Figure 3B). Also, comparison of nigral
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FIGURE 3 | Alpha synuclein associated neurotoxicity in the SL1SL2 rat model. (A) Representative TH immunohistochemical staining of nigral sections in
animals injected with AAV8-SL1SL2 at 1 and 4 weeks. Scale bar represents 250µm. (B) illustrates in a graph bar the estimation of total TH+ cells in the SN
(expressed as % of non-injected side) using unbiased stereological counting at 1 and 4 weeks. 38.5 ± 7.5% significant dopaminergic cell loss was found at 4 weeks
when compared to the non-injected side [Paired Students’ T-test, T(9)= 5.0, **p < 0.001] and One-way ANOVA analysis followed by a Tuckey’s for multiple testing
revealed a 33.81 ± 7.9% significant difference between 1 and 4 weeks (**p < 0.001). (C) Photomicrographs illustrating TH+ terminals in the STR in SL1SL2 animals.
Scale bars represent 2mm and 300µm (zoomed-in pictures). (D) Illustrates in a bar graph the quantitative densitometry of the TH+ fibers measurements (expressed
as percentage of non-injected side). The bars represent the average of four different rostro caudal levels of the STR measured for each animal. Statistical difference
was found at 4 weeks in the injected side compared to the non-injected side [Paired Students’ T-test, T(9) = 5.0, **p<0.001] and also between time point group
(**p < 0.001). n = 6, for 1 week group and n = 8, for 4 weeks group.
neurons at 1 and 4 weeks revealed a significant difference
in the extent of cell loss between the groups. Dopaminergic
cell death was further corroborated by the loss of fibers in
the STR (Figures 3C,D). Densitometric analysis of TH stained
sections showed a dense innervation throughout the STR of
the non-injected side at all-time points. This was also true
of the injected side at 1 week (Figures 3C,D OD black bar
= 96.9 ± 2.2%). By contrast, at 4 weeks the injected side had
a significant reduction of striatal TH+ fibers of 27.7 ± 7.4%
relative to the contralateral side (Figure 3D). Thus, these data
demonstrate a progressive cell and terminal loss through 4
weeks.
Modulation of αSyn Oligomerization in the
Rodent Bioluminescent PCA Model
The fact that αsyn oligomers can be detected in the SN as soon
as 1 week post virus delivery make this a very attractive model
for rapid screening of modulators of αsyn oligomers. Therefore,
we performed a proof-of-concept experiment whereby rats were
treated with a previously described heat shock protein inhibitor,
SNX-9114 (McFarland et al., 2014). In vitro αsyn-induced
aggregation and toxicity is prevented by inhibition of Hsp90
(Klucken et al., 2004; McLean et al., 2004; Danzer et al., 2011;
Jones et al., 2014). Hsp90 inhibition results in activation of heat
shock factor 1 and by consequence an up-regulation of protective
stress-induced proteins such as Hsp70. We recently showed a
novel class of Hsp90 inhibitors that could significantly reduce
αsyn oligomerization in a cellular model of αsyn aggregation
(Putcha et al., 2010; McFarland et al., 2014).
Here we chose to use the Hsp90 inhibitor to validate our
1 week oligomers model. Because SNX-9114 has not been
previously validated in vitro, we first evaluated its ability to
reduce αsyn oligomer formation in our in vitro complementation
assay. Stable cells expressing SL1 and SL2 were plated in a 96-
well plate format and treated with 0.01% DMSO or increasing
concentrations of the SNX-9114 (25, 50, 100, and 200 nM).
Twenty-four hours later, cells were assayed for luciferase activity
to determine the effect of the inhibitor on αsyn oligomerization
as measured by reconstituted luciferase activity. A decrease
in luciferase activity was first detected at 25 nM and 50 nM
(Figure 4A, p > 0.05), however, at higher doses (100 and
200 nM) SNX-9114 significantly reduced αsyn oligomerization
by 32.48 ± 2 and 35.1 ± 4.2% respectively compared to DMSO
(Figure 4A, p < 0.05). Biochemical analysis of cells expressing
SL1SL2 and treated with SNX-9114 confirmed the up-regulation
of Hsp70 in a dose-dependent manner (Figure 4B) with little to
no effect on steady state levels of αsyn except at the highest doses
(Figure 4B).
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FIGURE 4 | Effect of SNX-9114 on αsyn oligomerization in cell culture. (A) A range of concentrations of SNX-9114 was added to SL1SL2 cells stably
overexpressing hαsyn for 24 h. The extent of intracellular αsyn oligomers was evaluated by luciferase assay and was normalized to DMSO control. Oligomerization was
significantly decreased with a 100 and 200 nM doses (*p < 0.05). (B) Induction of Hsp70 after treatment with SNX-9114 on SL1SL2 cells was monitored by western
blot as well as the expression of h-αsyn. Actin was used as a loading control. Data are given as mean ± S.E.M., from three independent experiments. Statistical
analysis: One-way ANOVA followed by Tuckey’s multiple comparison test. n.s., not significant.
To determine if Hsp90 inhibition could reduce αsyn oligomer
formation in vivo after 1 week, we stereotactically injected AAV-
SL1 and AAV-SL2 into rat SN as described previously. Forty-
eight hours after surgery we orally gavaged the rats with 2mg/kg
SNX-9114 or vehicle control. A second gavage of 2mg/kg SNX-
9114 or vehicle was performed 2 days later, and the rats were
sacrificed at 7 days post-surgery (Figure 5A) A control group
of rats transduced with AAV-hGluc were included to control for
drug effects on the luciferase enzymatic reaction.
Western blot of homogenates prepared from the SN of
injected rats confirmed the induction of Hsp70 in animals
treated with SNX-9114 compared to animals treated with vehicle
(Figure 5B). Furthermore, a luciferase activity assay on the
same homogenates demonstrated a significant decrease in αsyn
oligomers in the group of animals receiving the Hsp90 inhibitor
(Figure 5C). No significant difference in hαsyn protein levels
was detected between the drug and vehicle control groups when
measured by ELISA (Figure 5D, p > 0.05). Of note, consistent
with our in vitro experiments (Figure 4B), SNX-9114 did not
directly affect the enzymatic luciferase signal in vivo (Figure 5E).
These findings suggest that the decreased luciferase signal in the
Hsp90 inhibitor treated group is indicative of less αsyn oligomer
formation (Figure 5C).
DISCUSSION
Neuropathologic and genetic studies have provided strong
evidence for the involvement of aggregated αsyn in the
pathogenesis of synucleopathies (Tu et al., 1998; Dickson et al.,
1999; Narhi et al., 1999; Masliah et al., 2000). Our present
study proposes a rapid model for tracking αsyn oligomerization
in selected brain regions of the rat brain using an ex vivo
bioluminescent PCA.
Herein we demonstrate that, our split hGluc AAV-SL1 and
SL2 vectors can be utilized to track αsyn oligomerization in vivo.
As early as 1 week, we observe the expression of the transgenes
along the nigrostriatal pathway and αsyn oligomers in the SN
(Figures 1, 2). At this time point no toxicity is detected in the SN
and no loss of dopaminergic fibers at the striatal level (Figure 3).
The expression of hαsyn and presence of oligomers in SN but
no cell loss as early as 1 week post-transduction make this an
attractive model with which to screen for novel oligomerization
modulators. Because no significant difference was detected in
total αsyn levels between SN and STR at 1 week, the absence of
αsyn oligomers in STR suggests distinct dynamics of oligomer
formation in striatum compared to SN or alludes to oligomer
formation occurring in the soma and subsequent trafficking of
oligomers to the terminals where additional oligomer formation
is seeded. Differentiating between these two mechanisms will
require further investigation.
By 4 weeks, abundant αsyn oligomers are detected in both
SN and STR and cell loss is detected in the SN, with terminal
loss detected in the STR. αSyn expression in the SN and STR
did not increase even though there was a 13-fold increase
in luciferase activity. These data could support a hypothesis
whereby increased asyn oligomers correlate to neurotoxicity,
however further studies will be required before this can be
confirmed.
Given the essential role of αsyn oligomers in the pathogenesis
of synucleopathies it is essential that we develop reliable methods
for their detection. Oligomer-specific αsyn antibodies (Emadi
et al., 2009; Fagerqvist et al., 2013; Maetzler et al., 2014)
recognizing relevant pathology have been designed and are
relevant for immunohistochemistry of αsyn brain pathology on
human or transgenic mouse (Delenclos et al., 2015; Sengupta
et al., 2015). They also hold potential as therapies and could be
a relevant disease biomarkers. However, such antibodies cannot
monitor the oligomeric state of αsyn in a live cell environment.
PCA strategies using fluorescence or bioluminescence reporters
have been developed and have proven to be a powerful approach
to study protein aggregation. Recently, we generated a rodent
model using YFP venus PCA to monitor αsyn oligomerization
in live animals (Dimant et al., 2014). Using fluorescence as
readout, we directly detected αsyn oligomers andmonitored αsyn
aggregation in cortical neurons of living mice using two photon
microscopy. Recently, a mouse model expressing firefly luciferase
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FIGURE 5 | Effect of SNX-9114 in SL1SL2 rat substantia nigra. (A) Illustration of the timeline experiment of SNX-9114 treatment in vivo. (B) Hsp70 induction in
the SN was evaluated by western blotting and actin was used as a loading control. Western blot shows four representative animals for each group. (C) Level of
oligomers in the SN of the vehicle group (n = 6) and the treated group (n = 6) was assessed by luciferase activity 1 week after viral vector delivery. A significant
decrease of αsyn oligomerization was observed after 2mg/kg SNX-9114 treatment [Student’s T-test, T(9) = 2.46; *p < 0.05]. (D) Expression of hαsyn in injected SN
homogenate was analyzed by ELISA and is expressed as amount of hαsyn normalized to the total amount of protein in the homogenates. (E) Control rats injected with
hGluc and treated either with vehicle (n = 2) or SNX-9114 (n = 2). The luciferase activity was not affected by the drug treatment as p > 0.05. n.s, not significant.
tagged-αsyn in vivo was generated and bioluminescent imaging
(IVIS) was used to non-invasively capture αsyn oligomerization
in the mouse brain (Aelvoet et al., 2014). Both of these in vivo
models have distinct advantages such as the ability to follow
the response in the same animals over time, providing a
kinetic readout of the oligomerization process. In our model
we measure the oligomerization ex-vivo. Although, all brains
were processed at the same time and under the same conditions,
we cannot exclude the possibility that the extraction procedure
could perturb αsyn aggregation state. On the other hand, even
though in vivo imaging represents a good tool to monitor
αsyn, these methods require expensive instrumentation, are
time-consuming, and involve anesthesia and systemic substrate
injections in the case of the firefly luciferase PCA. Lastly, the two
photon microscopy is limited by photo absorption of the tissue
and does not allow deep brain structure imaging.
The model presented herein has the advantage of having
a rapid readout without expensive equipment. HGluc may
also provide increased sensitivity as it is over 100-fold more
sensitive than the commonly used luciferases, Firefly, and Renilla
reniformis (Tannous et al., 2005; Remy and Michnick, 2006).
Also Gluc is a smaller reporter (185 amino acid; Tannous
et al., 2005) compared to the other forms of luciferase or the
fluorescence reporter. Finally, hGluc PCA is a fully reversible
interaction unlike the assay based on YFP venus fluorophore,
thus facilitating the detection of the kinetics of protein complex
assembly/disassembly in vivo. Better spatial and temporal
resolution can be achieved compared with in vivo imaging and
we believe that hGluc PCA may be more efficient and effective
for some approaches. In our current experiment, oligomers
were quantified ex vivo for several reasons. Brain lysate analysis
provides a more accurate semi quantitative measure of aggregates
and most importantly, allows a combination of different analyses
on the same sample (e.g., ELISA, WB) for each brain. Because
the PCA assay is effective in tissue directly placed in a micro
titer plate, its utility to measure oligomers in in vivo brain slice
preparations is also a possibility. Also, it is well established that
αsyn oligomers can be transmitted from neuron(s) to neuron(s),
thus inducing pathology along neuroanatomical pathways in the
brain (El-Agnaf et al., 2006; Emmanouilidou et al., 2010). It
remains to be determined if αsyn induces neurodegeneration via
intracellular- or extracellular-associated mechanisms. Our AAV-
model, coupled with in vivo microdialysis, could be a useful tool
for the detection and analysis of αsyn oligomers in the interstitial
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fluid (ISF) of living animals, allowing a real time monitoring of
in vivo processes and opening possibilities for αsyn transmission
studies. One disadvantage is that coelenterazine, the substrate
of hGluc, does not cross the blood brain barrier and therefore
excludes the use of our model for imaging in live animals. Despite
this limitation, the use of hGluc PCA in vivo provides a rapid
model to track αsyn oligomers depending on the desired readout.
To investigate the potential of our in vivo bioluminescent
PCA to identify compounds that interfere with αsyn-αsyn
interaction or modulate oligomerization, in a little as 1 week,
we administered a cohort of AAV SL1 and SL2 transduced rats
with 2mg/kg SNX-9114, for one week. Hsp90 inhibition has
been shown to modulate αsyn aggregation and toxicity (Auluck
et al., 2002; Kalia et al., 2010; Luo et al., 2010; Putcha et al.,
2010) and we have previously established that pharmacological
pretreatment with geldanamycin, a naturally occurring Hsp90
inhibitor, protects against αsyn-induced toxicity and leads to
degradation of high molecular-weight species (McLean et al.,
2004) More recently we described the efficacy of novel brain
permeable Hsp90 inhibitors to reduce the formation of αsyn
oligomeric species in a dose dependent manner using our
bioluminescent PCA system in H4 neuroglioma cells (Putcha
et al., 2010). In line with these previous data, we show here
that an Hsp90 inhibition can inhibit αsyn oligomerization in our
AAV-SL1 and AAV-SL2 rodent model, and most importantly,
we demonstrated that our luciferase assay is sensitive enough to
detect these changes. In addition it is noteworthy to mention
that the level of oligomers was assessed as early as 1 week
after the AAV-injection, at a time when we do not detect cell
death (Figure 3B) but we have an abundance of oligomers in
the SN (Figure 2A). Therefore, the detected decrease in luciferase
activity at 1 week in SN in animals receiving Hsp90 inhibitor, can
be directly attributed to a decrease of αsyn oligomers.
While several strategies have been developed to monitor the
modulation of αsyn aggregation in vivo and in vitro, the major
advantage of the present approach over other techniques is the
ability to quantify a change in αsyn oligomerization in a short
period of time (1 week) with a fast, simple, and sensitive assay.
In conclusion, our bioluminescent in vivo model represents a
powerful new tool to study spatial and temporal changes in αsyn
aggregation in response to new therapeutic agents that modulate
αsyn oligomerization.
AUTHOR CONTRIBUTIONS
MD carried out the study design, animal procedures, histology,
analysis, and drafting of the manuscript. TT performed
immunohistochemistry, stereology analysis, densitometry
analysis, and participated in all animal procedures. DJ,
participated in the study design, animal procedures, and
editing of the manuscript. SM and AB performed the in vitro
assay. MY, assisted with animal procedures. WH provided the
compound SNX-9114. PM participated in the experimental
design, coordination, interpretation, drafting, and editing
of the manuscript. All authors read and approved the final
manuscript.
ACKNOWLEDGMENTS
We thank the Mayo Clinic Viral Vector core, Ms. Karen Jansen-
West, Ms. Ena Whitelaw, and Ms Emilie Perkerson for high titer
AAV production. This work was funded by NIH NS073740 to
PM.
SUPPLEMENTARY MATERIAL
The Supplementary Material for this article can be found
online at: http://journal.frontiersin.org/article/10.3389/fnins.
2015.00511
Supplementary Figure 1 | Luciferase activity in control rats. (A) Animals
were stereotactically injected with one viral vector (AAV8-SL2, n = 2). After 4
weeks, the luciferase activity was measured. No specific signal was detected in
the injected side since the luciferase activity was similar to the non-injected side.
In both regions, SN (A) and STR (B,C) To verify that the complementation occurs
in vivo and not during homogenization process, animals were injected with
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homogenate of SN left and right or STR left and right, were mixed together
respectively and luciferase activity was measured. No activity was detected in the
mixture of SN or STR.
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